Daily Stock Analysis, ADHD, Alcobra Ltd, priceseries

Alcobra Ltd. Daily Stock Analysis
Stock Information
Open
1.15
Close
1.13
High
1.16
Low
1.12
Previous Close
1.14
Daily Price Gain
-0.01
YTD High
2.58
YTD High Date
Jan 6, 2017
YTD Low
0.83
YTD Low Date
Jan 17, 2017
YTD Price Change
-1.08
YTD Gain
-48.87%
52 Week High
5.36
52 Week High Date
Aug 29, 2016
52 Week Low
0.83
52 Week Low Date
Jan 17, 2017
52 Week Price Change
-3.06
52 Week Gain
-73.03%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 5. 2015
3.95
Jan 28. 2015
6.35
16 Trading Days
60.76%
Link
LONG
Feb 13. 2015
6.92
Mar 3. 2015
7.27
11 Trading Days
5.06%
Link
LONG
May 22. 2015
6.50
Jun 9. 2015
7.27
11 Trading Days
11.89%
Link
LONG
Jul 10. 2015
6.46
Jul 30. 2015
7.38
14 Trading Days
14.20%
Link
LONG
Sep 18. 2015
8.26
Sep 21. 2015
8.70
1 Trading Days
5.33%
Link
LONG
Oct 23. 2015
6.73
Nov 10. 2015
7.82
12 Trading Days
16.19%
Link
LONG
Apr 1. 2016
3.93
Apr 26. 2016
4.37
17 Trading Days
11.13%
Link
LONG
May 16. 2016
4.17
Jun 9. 2016
5.33
17 Trading Days
27.90%
Link
LONG
Jun 29. 2016
4.34
Jul 12. 2016
4.63
8 Trading Days
6.64%
Link
LONG
Aug 2. 2016
4.37
Aug 19. 2016
4.95
13 Trading Days
13.16%
Link
LONG
Dec 19. 2016
2.10
Dec 28. 2016
2.23
6 Trading Days
6.43%
Link
Company Information
Stock Symbol
ADHD
Exchange
NasdaqGM
Company URL
http://www.alcobra-pharma.com
Company Phone
972722204661
CEO
Yaron Daniely
Headquarters
-
Business Address
AZRIELI TRIANGLE BUILDING, 132 DERECH MENACHEM BEGIN, 39TH FLOOR, TEL AVIV, ISRAEL 6701101
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001566049
About

Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel.

Description

Alcobra Ltd., a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company is primarily developing MDX (metadoxine), an onset/extended release formulation of the chemical pyridoxine pyroglutamate, which is in Phase III clinical trial for adults with attention deficit hyperactivity disorder (ADHD); in Phase II clinical trial for pediatric with ADHD; and which is completed Phase II clinical trial in adolescents and adults with Fragile X Syndrome. Alcobra Ltd. was founded in 2008 and is headquartered in Tel Aviv, Israel.